Drug Discovery Online Downloads

Application Note: Evaluation Of PARP Inhibitors: Performed On BMG LABTECH's FLUOstar Omega

Thu, 02 Jul 2009 03:51:00 GMT

Poly ADP-ribosylation is a post-translational modification of proteins that plays a crucial role in regulating DNA repair. Poly (ADP-ribose) polymerase (PARP) transfers ADP-ribose to itself and other nuclear proteins such as histones. The substrate for that reaction is NAD+. By BMG LABTECH, GmbH

White Paper: Research Efficiency In Hard Times: It's Time To Adapt

Tue, 23 Jun 2009 05:03:00 GMT

Nobody likes hard times, but they do have one redeeming quality: They focus attention on areas neglected in good times. The need for greater efficiency is a prime example, especially for small drug development companies. Even in the best of times, they must cope with the formidable combination of high costs, long timelines, and low success rates. And when hard times come, they feel it first and most acutely. These companies should be the first to ask: Is there a better way? By Michael Rosenberg, M.D., MPH, Life Science Leader magazine

Case Study: Guilty Or Not Guilty: Justice Is Served With XP205 Semi-Microbalance

Tue, 16 Jun 2009 05:10:00 GMT

The independent Forensic Scientific Service (FND) of the State Police in St. Gallen, Switzerland conducts analytical and forensic tests with the aim of detecting proof of suspected crimes such as the illegal possession of drugs. As samples are generally available in powder form and in rather small quantities, an XP205 semi-microbalance was the customer's solution to assist in their delicate weighing tasks. By Mettler-Toledo, Inc.

Datasheet: Biologics Manufacturing

Thu, 11 Jun 2009 05:14:00 GMT

Abbott offers you state-of-the-art Biologics Manufacturing Capabilities, including Smart solutions to process design, analytical characterization and cGMP manufacturing, supporting the development and commercialization of your biopharmaceutical product.

Flyer: Quality Assurance/Quality Control (QA/QC)

Tue, 09 Jun 2009 14:33:49 GMT

The objective of PYRAMID Laboratories, Inc. (PYRAMID's) Quality Assurance (QA) program is to ensure that all manufacturing processes and data collected are scientifically valid, of known precision and accuracy and properly documented.

Datasheet: Mustang® Q XT Ion Exchange Chromatography Capsules

Fri, 22 May 2009 07:01:00 GMT

Mustang Q XT capsules have been designed for optimum membrane chromatography performance, providing scalability from process development through to full scale manufacturing.

Datasheet: Q And S HyperCel™ Chromatography Sorbents

Fri, 22 May 2009 06:13:00 GMT

Q and S HyperCel sorbents are composed of a rigid cellulose matrix that has excellent flow properties and generates low backpressure, compatible with the needs of large-scale protein production.

Realize Your Cytotoxic Agent's Unique Potential

Mon, 18 May 2009 12:00:00 GMT

Product Brochure: Cytotoxic Manufacturing

Add A Powerful Ingredient To Your Parenteral Manufacturing

Mon, 18 May 2009 11:58:00 GMT

Product Brochure: Parenteral Manufacturing

Flyer: About PYRAMID Laboratories

Wed, 13 May 2009 07:15:00 GMT

PYRAMID Laboratories, Inc. (PYRAMID), established in 1988, is located in southern California, USA. Our facilities are housed in three (3) buildings covering over 50,000 sq. ft.

Flyer: Pharmaceutical Development Services

Wed, 13 May 2009 07:07:00 GMT

The scientific staff at PYRAMID Laboratories, Inc. has more than 30 years of experience across all areas of parenteral formulation and manufacturing. From pre-clinical through clinical and on to commercial manufacturing, PYRAMID focuses on optimizing your product's stability and performance.

Flyer: PYRAMID Laboratories Lyophilization Services

Wed, 13 May 2009 06:27:00 GMT

PYRAMID's goal in the development of a lyophilized drug product is to produce a pharmaceutically elegant and physico-chemically stable product that can be easily reconstituted and administered to the patient. Scientists at PYRAMID have the background and knowledge in lyophilization technology to assist you in reaching that goal for your drug product.

Article: Managing Solid Waste From Single- Use Systems In Biopharmaceutical Manufacturing

Tue, 31 Mar 2009 06:09:00 GMT

The increasing implementation of single-use systems (SUS) in biopharmaceutical manufacturing has been driven by multiple factors including cost reduction, increased flexibility, improved process development time, and reduced capital investment. By H�l�ne Pora and Bruce Rawlings

Article: Implementing Single-Use Technology In Biopharmaceutical Manufacturing

Tue, 31 Mar 2009 05:55:00 GMT

In biopharmaceutical manufacturing, single-use components and systems can offer distinct advantages over reusable, cleanable systems. Deciding whether to move to a single-use approach, however, depends on many factors. By Weibing Ding and Jerold Martin

Case Study: Introducing Disposable Systems Into Biomanufacturing

Tue, 31 Mar 2009 05:39:00 GMT

Single-use (disposable) systems are being considered and introduced into many biopharmaceutical processes because manufacturers have identified significant benefits they offer over traditional reusable systems. By Mark Fuller and H�l�ne Pora

Article: Applying Good Engineering Practices To The Design Of Single-Use Systems

Tue, 31 Mar 2009 05:21:00 GMT

Significant changes are being incorporated into biopharmaceutical manufacturing processes as a result of drivers such as increasingly strict regulatory demands, reduction of manufacturing costs, and outsourcing to contract manufacturing organizations (CMOs). By Martyn Botterill and Bruce Rawlings

Article: A Prescriptive Approach To Management Of Solid Waste From Single-Use Systems

Tue, 31 Mar 2009 04:30:00 GMT

In biopharmaceutical manufacturing, the disposal of solid waste from single-use systems is becoming an increasingly important issue. The new focus is driven by several major factors including a broadening range of disposable technologies enabling, in some cases, the installation of completely disposable multistage systems; improved scalability of singleuse components offering production capacities to thousands of liters; and the environmental impact of waste disposal. By Bruce Rawlings and H�l�ne Pora

Article: Environmental Impact of Single-Use And Reusable Bioprocess Systems

Tue, 31 Mar 2009 04:10:00 GMT

Bioprocess manufacturing systems have incorporated single-use/disposable components for more than 50 years and have demonstrated welldefined process benefits from their use (1-6). The environmental impact of single-use technologies, however, has been a major focus of attention only in recent years. By Bruce Rawlings and H�l�ne Pora

EUDRAPULSE®

Tue, 30 Dec 2008 05:49:00 GMT

EUDRAPULSE® enables rapid, immediate (pulsed) drug release after a defined lag time. A layer composed of drug and organic acid, or its salt, is applied to a core acting as the carrier, which is coated with EUDRAGIT® RL/ RS.

EUDRACOL®

Tue, 30 Dec 2008 05:37:00 GMT

EUDRACOL® gives Pharma Polymers a multi-unit technology that provides targeted drug delivery direct to the colon, with delayed and uniform drug release. The system consists of several layers. At the center is a core containing the active.